Introduction
Worldwide, 387 million people are estimated to be living with diabetes mellitus. 1 In China, diabetes affected 113.9 million adults in 2010, indicating that China had more people with diabetes than any other country. 2 The American Diabetes Association (ADA) and the International Diabetes Federation (IDF) recommend a glycemic treatment target for HbA1c of approximately ≤7.0 % for most patients. 1, 3, 4 A more aggressive HbA1c treatment goal of 6.5 % has been recommended by the IDF and the American Association of Clinical Endocrinologists (AACE), 4, 5 as well as the ADA in individual patients if it can be achieved without significant hypoglycemia or other adverse events. 3 Despite these recommendations, many patients fail to achieve optimal glycemic control.
The progressive nature of type 2 diabetes mellitus (T2DM) contributes to the failure to reach glycemic targets in many patients and, as a result, treatment with a combination of different antihyperglycemic agents (AHAs) is now widely accepted. 6 Given the β-cell failure noted in patients with T2DM, 7 treatment with sulfonylureas, with or without metformin, is a common paradigm. Sulfonylureas improve blood glucose levels by stimulating insulin secretion from pancreatic β-cells in a non-glucose-dependent manner 8 and metformin, a biguanide, acts primarily by lowering hepatic glucose production and may also improve insulin resistance. 9, 10 However, patients treated with a sulfonylurea or with the combination of a sulfonylurea plus metformin may not achieve or maintain glycemic control, 11 and the addition of other oral AHA medications, including thiazolidinediones (TZDs), dipeptidyl peptidase (DPP)-4 inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, or sodium-glucose cotransporter 2 (SGLT2) inhibitors, is recommended by the ADA and the European Association for the Study of Diabetes (EASD). 12 Sitagliptin (JANUVIA; Merck & Co., Inc., Kenilworth, NJ, USA) is an orally active, selective DPP-4 inhibitor approved in many countries, including China, as an adjunct to diet and exercise for the treatment of patients with T2DM. In global studies, sitagliptin treatment improved glycemic control as monotherapy and in combination with metformin in Chinese patients, and as monotherapy and in combination with other oral agents (metformin, a TZD, a sulfonylurea or a sulfonylurea or TZD in combination with metformin) and insulin (with or without metformin). 13, 14 Previously, in a global study of the safety and efficacy of the addition of sitagliptin treatment in patients failing glimepiride alone or in combination with metformin, it was shown that, in patients who had failed to achieve adequate glycemic control (i.e. HbA1c 7.5 %-10.5 %) on glimepiride therapy (with or without metformin), sitagliptin was generally well tolerated and provided significant improvements in HbA1c, fasting plasma glucose (FPG) and 2-h post-meal glucose (PMG) compared with placebo. 15 The present study, conducted in China, assessed the safety and efficacy of sitagliptin compared with placebo in Chinese patients with T2DM who had failed to achieve adequate glycemic control with a sulfonylurea (either glimepiride or gliclazide) alone or in combination with metformin.
Methods

Patients
Men and women aged ≥18 to ≤79 years, with T2DM, on stable doses of gliclazide (modified release ≥60 mg/day or immediate release ≥160 mg/day) or glimepiride (≥3 mg/day), with or without metformin (≥1500 mg/ day) for at least 10 weeks, and HbA1c ≥7.5 % and ≤11.0 % were eligible for inclusion in the present study. At screening, patients were excluded if they had a history of type 1 diabetes or intolerance, hypersensitivity or contraindication to sitagliptin, gliclazide or glimepiride, or metformin. Patients with active liver disease (including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease), new or worsening signs of coronary heart disease within 3 months (including acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder), severe peripheral vascular disease, or exclusionary laboratory values were also excluded. Women with a positive pregnancy test were excluded; those with reproductive potential were required to remain abstinent or use an acceptable method of birth control throughout the study period.
Study design
The present study was a 24-week Phase III multicenter randomized double-blind placebo-controlled clinical trial conducted at 32 centers in China from July 2012 to June 2014 (Merck Protocol PN253, clinicaltrials.gov: NCT01590771). The study was conducted in conformance with Good Clinical Practice standards and applicable country and local statutes and regulations regarding ethics committee review; written informed consent was obtained from each subject prior to performing any study-related procedure.
Sitagliptin 100 mg or matching placebo was supplied as an oral tablet in a blinded manner. In addition to ongoing open-label therapy with stable doses of gliclazide or glimepiride with or without metformin, during the 2-week single-blind placebo run-in period patients were instructed to take one tablet of placebo matching sitagliptin 100 mg/day. The randomized allocation schedule for study treatment assignment was performed via a computer-generated allocation schedule and implemented by an interactive voice response system (IVRS). Patients who met the inclusion criteria at the end of the placebo run-in period were randomized via the IVRS in a 1:1 ratio to sitagliptin or placebo treatment. During the 24-week double-blind treatment period, patients were instructed to take one tablet of sitagliptin 100 mg or matching placebo per day. Open-label gliclazide, glimepiride, and metformin were administered as recommended in the China drug label through the end of the double-blind treatment period and doses were kept constant unless down-titration was required for hypoglycemia.
A meal tolerance test (MTT) was conducted at randomization and at Week 24. At Visit 2 (Week À2), the first dose of single-blind sitagliptin placebo was taken at the clinic as a witnessed dose after the completion of all procedures. At Visit 3 (Day 1), the first dose of double-blind sitagliptin or matching placebo was taken at the clinic after completion of all procedures and after the blood samples for the MTT were taken, which was 120 min after the start of the standard meal (consisting of approximately 460 kcal, including 75 g carbohydrate, 9 g fat, and 18 g protein). At Week 24, the last dose of double-blind sitagliptin or matching placebo was taken at the clinic as a witnessed dose after fasting blood samples were collected and 30 min prior to ingesting the standard meal for the MTT. Open-label study medications (gliclazide or glimepiride, with or without metformin) were taken after fasting blood samples were collected and just prior to ingesting the standard meal for the MTT.
Study assessments
The primary efficacy endpoint was the change from baseline in HbA1c after 24 weeks of add-on treatment with sitagliptin compared with placebo in patients taking a sulfonylurea, alone or in combination with metformin (overall cohort). Secondary efficacy endpoints included the change from baseline in HbA1c, 2-h PMG (following a standard meal), and FPG after 24 weeks of add-on treatment with sitagliptin compared with placebo in each metformin stratum and the overall cohort. The percentage of patients at HbA1c goals (<7.0 % and <6.5 %) at Week 24, and the changes from baseline in fasting insulin, homeostatic model assessment of β-cell function (HOMA-β), homeostasis model assessment of insulin resistance (HOMA-IR), and the quantitative insulin sensitivity check index (QUICKI) were assessed at Week 24. Changes from baseline in lipids, including total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides, were also measured in the individual metformin strata and the overall cohort.
Safety and tolerability were assessed by physical examination, collection of adverse events (AEs), vital signs, body weight, laboratory safety studies, and locally read electrocardiograms (ECGs). Laboratory safety studies included blood chemistry (including alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin, alkaline phosphatase, and creatine phosphokinase), hematology (including a complete blood count [CBC], differential and absolute neutrophil count, and platelet count), urinalysis, and urine pregnancy testing.
Statistical analyses
It was expected that 200 patients per treatment group would be available for the analysis for the primary hypothesis. Based on a standard deviation (SD) of 1.0 %, this sample size would provide 90 % (80 %) power to detect a difference of 0.32 % (0.28 %) in the mean change from baseline in HbA1c between the treatment groups (two-sided test, α = 0.05).
The full analysis set (FAS) population was used for all efficacy analyses, defined separately for each analysis endpoint, and comprised all patients who received one or more doses of study therapy, except for the following: 1. For analyses that used the analysis of covariance (ANCOVA) method, the FAS excluded patients who did not have one or more observations for the analysis endpoint subsequent to the first dose of study treatment, or who did not have baseline data for the analysis endpoint. 2. For analyses that used the constrained longitudinal data analysis (cLDA) model, the FAS population excluded patients who did not have one or more measurements for the analysis endpoint (baseline or subsequent to the first dose of study treatment). 3. For analyses that use the Miettinen and Nurminen method, the FAS excluded patients who did not have one or more observations for the analysis endpoint subsequent to the first dose of study treatment.
The change from baseline in HbA1c at Week 24 was analyzed using an ANCOVA model controlled for treatment, metformin stratum (on or not on metformin), and baseline HbA1c value. The primary hypothesis regarding superiority of sitagliptin compared with placebo in decreasing HbA1c was assessed using the estimated treatment difference under the ANCOVA model. This model was based on the assumption that model-based residuals follow a normal distribution. For highly nonnormal residuals (P < 0.001), the primary analysis for the above parameters was conducted using a robust regression (RREG) approach (see supplementary materials for results). Endpoints related to HbA1c for each individual metformin stratum were evaluated only if the primary efficacy endpoint test was successful. A cLDA method proposed by Liang and Zeger 16 was used as a secondary method for handling missing data for primary and secondary efficacy endpoints. The Hochberg method was used for multiplicity adjustment to control the overall Type I error rate at α = 0.05 across the first two secondary endpoints.
The secondary endpoints were supportive and were evaluated in a conditional manner with priority order. The 2-h PMG-related endpoints were tested only if the corresponding HbA1c endpoint tests were successful, and the FPG-related endpoints were tested only if the corresponding 2-h PMG endpoint test was successful. Analyses of the percentages of patients at the HbA1c goals of <7.0 % and <6.5 % at Week 24 were conducted using the Miettinen and Nurminen method. 17 The differences in proportions and relative risks, along with the corresponding 95 % confidence intervals (CIs) were calculated. The last observation carried forward (LOCF) method was used to determine whether a value met the goal when the HbA1c result at Week 24 was not available. Safety analyses were conducted in the all-patientsas-treated (APaT) populations, which included all patients who received one or more doses of study drug.
Results
In all, 764 patients were screened and 498 were randomized (249 each to sitagliptin or placebo; Fig. 1 ). The most common reason for screen failure was not meeting the HbA1c entry criteria, followed by not meeting other required laboratory values. Fifty-eight (11.6 %) patients discontinued the study, with more patients discontinuing from the placebo group (n = 39) than the sitagliptin group (n = 19). The most common reasons for discontinuation were withdrawal by subject and protocolspecified criteria (Fig. 1 ). In total, 230 patients in the sitagliptin group and 210 patients in the placebo group completed the 24-week double-blind treatment period.
Baseline assessments of demographic, anthropometric, disease characteristics and efficacy endpoints were comparable between the treatment groups ( Table 1) . For the overall cohort, the mean duration of T2DM was 7.0 years and the mean HbA1c level was 8.5 %. There were no meaningful differences between treatment groups in frequency or type of baseline medical conditions or the use of other concomitant medications. Mean compliance to study medication was 98.6 % in both treatment groups.
The reduction in HbA1c from baseline at Week 24 was significantly greater in the sitagliptin group than in the placebo group, with an estimated betweentreatment difference (95 % CI) of À0.61 % (À0.77 %, À0.44 %; P < 0.001; Table 2 ). The reduction in HbA1c from baseline over time to Week 24 in the overall cohort is shown in Fig. 2 . The addition of sitagliptin treatment resulted in greater HbA1c reductions from baseline at Week 24 compared with placebo in each metformin stratum (Table 2 ; P < 0.001). The least squares mean change (95 % CI) from baseline in the sitagliptin group was similar across each metformin stratum, whereas the change from baseline in the placebo group was greater in the subgroup of patients on metformin than in the subgroup of patients not on metformin ( Table 2 ).
The addition of sitagliptin treatment significantly in- Sitagliptin reduced 2-h PMG significantly more than placebo at Week 24 in the overall cohort and in each metformin stratum ( Table 2 ). The between-treatment differences (95 % CIs) in least squares mean change from baseline were À32.9 mg/dL (À45.4, À20.4 mg/dL; P < 0.001) for the overall cohort, À27.2 mg/dL (À41.2, À13.2 mg/dL; P < 0.001) for the subgroup of patients on metformin, and À37.7 mg/dL (À56.9, À18.4 mg/ dL; P < 0.001) for the subgroup of patients not on metformin.
Similarly, the reduction in FPG was significantly greater with sitagliptin than with placebo at Week 24 in the overall cohort and in each metformin stratum (Table 2 ; Fig. S1 ). The estimated between-treatment difference (95 % CIs) in least squares mean change from baseline was À16.8 mg/dL (À23.3, À10.2 mg/dL; P < 0.001) in the overall cohort, À16.5 mg/dL (À25.3, À7.8 mg/dL; P < 0.001) in the subgroup of patients on metformin, and À17.0 mg/dL (À26.9, À7.1 mg/dL; P < 0.001) in the subgroup of patients not on metformin.
No statistically significant difference was observed between the treatment groups in the overall cohort for change from baseline at Week 24 in fasting insulin, HOMA-β, HOMA-IR, or QUICKI, with least squares mean difference (95 % CIs) of À0.4 (À3.0, 2.1; P = 0.739), 147.1 (À180.1, 474.3; P = 0.377), À0.3 HbA1c and 2-h post-meal glucose (PMG) analyses were based on robust regression using M-estimation with terms for treatment and the metformin stratum, and baseline efficacy parameter as a covariate. Fasting plasma glucose (FPG) was based on robust regression using M-estimation with terms for treatment and the metformin stratum, and baseline FPG as a covariate.
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HbA1c was based on an analysis of covariance (ANCOVA) model with terms for treatment and baseline efficacy parameter as a covariate. The 2-h PMG and FPG were based on robust regression using M-estimation with terms for treatment and baseline efficacy parameter as a covariate.
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HbA1c and 2-h PMG were based on an ANCOVA model with terms for treatment and baseline efficacy parameter as a covariate. Fasting plasma glucose was based on robust regression using Mestimation with terms for treatment and baseline FPG as a covariate. 4 All differences were statistically significant at the P < 0.001 level.
CI, confidence interval; LS, least squares.
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(À1.3, 0.6; P = 0.494), and À0.0 (À0.0, 0.0; P = 0.371), respectively (Table S1 ). There were no statistically significant differences observed between the treatment groups in the percentage change from baseline at Week 24 in the overall cohort for lipids (for details, see supplementary section and Table S2 ).
Of the 498 patients randomized in the present study, 497 patients received double-blind study medication (248 patients in the sitagliptin group and 249 patients in the placebo group) and were included in the analyses of safety. A summary of AEs is presented in Table 3 . The proportion of patients reporting AEs was generally comparable between the sitagliptin and placebo groups. No deaths occurred during the study. A significantly higher proportion of patients in the sitagliptin group had one or more events of symptomatic hypoglycemia compared with the placebo group There were three SAEs related to cardiovascular events subject to adjudication by an expert committee blinded to treatment assignment. Of these, two were confirmed as cardiovascular SAEs and one was not able to be adjudicated. Confirmed adjudicated cardiovascular events included an event of unstable angina pectoris in Figure 2 Mean HbA1c over time for sitagliptin 100 mg (n = 231-248) and placebo (n = 213-249) in the entire study cohort. Data are the mean ± SE. Considered by the investigator to be related to the study medication. Study medication withdrawn. 4 Symptomatic episode: episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. 5 Severe episode: episode that required assistance, either medical or non-medical. Episodes with a markedly depressed level of consciousness, a loss of consciousness, or seizure are classified as having required medical assistance, whether or not medical assistance was obtained.
a patient in the sitagliptin group and an event of hemorrhagic stroke in a patient in the placebo group. During the study there were no clinically meaningful changes from baseline or between-group differences in the percentage of patients meeting criteria for the predefined limits of change (PDLC) for all selected laboratory endpoints. Mean changes in PDLC were generally low and comparable between the sitagliptin and placebo groups. No clinically relevant changes from baseline or between-group differences were observed at any time point for pulse rate, systolic blood pressure, diastolic blood pressure, or weight change (Table S3) , and no consistent trends over time were noted.
Discussion
Overall, 24 weeks of add-on treatment with sitagliptin to sulfonylurea, alone or in combination with metformin, resulted in significantly greater reductions in HbA1c, 2-h PMG, and FPG compared with the addition of placebo. Moreover, the proportion of patients achieving HbA1c levels <7.0 % was greater in the sitagliptin 100 mg group than in the placebo group. The addition of sitagliptin 100 mg was generally well tolerated, with a low incidence of AEs and SAEs, although the proportion of patients with symptomatic hypoglycemia was higher with sitagliptin than with placebo. To complement the HbA1c efficacy endpoint, measured primarily to identify the average plasma glucose concentration over the prior 2-3 months, PMG and FPG were also assessed. The greater reduction from baseline in both the 2-h PMG and FPG compared with the placebo group after 24 weeks are consistent with the overall superior reduction in HbA1c observed in the sitagliptin group.
Results of global studies of the addition of sitagliptin or other DPP-4 inhibitors in patients being treated with sulfonylurea monotherapy or sulfonylurea and metformin have been reported previously. [18] [19] [20] [21] [22] However, because the pathophysiology and evolution of T2DM in East Asian patients may not be identical to that observed in Caucasian patients previously studied in global trials, 23,24 demonstration of the safety and efficacy and of the addition of a DPP-4 inhibitor (sitagliptin) in Chinese patients being treated with sulfonylurea monotherapy or sulfonylurea and metformin is important and addresses a gap in the current knowledge about these agents. The present study, conducted in a Chinese population, yielded results generally consistent with a similarly designed multinational study, demonstrating that the addition of sitagliptin to a sulfonylurea, with or without metformin, in patients with inadequate glycemic control resulted in statistically significant and clinically meaningful reductions in HbA1c in the sitagliptin group compared with placebo. 15 The results from the present study are generally consistent with those from previous global studies where DPP-4 inhibitors have been added to sulfonylureas. In an 18-week study of linagliptin added to sulfonylurea monotherapy, 18 the change from baseline in HbA1c was numerically lower than the change from baseline in HbA1c at Week 24 in the present study among the subgroup of patients taking sulfonylurea monotherapy. Similarly, the change from baseline observed in the subgroup of patients taking sulfonylurea monotherapy in the present study was numerically higher than the change from baseline in HbA1c observed in saxagliptin 2.5 and 5 mg groups at Week 24, 19 or at Week 26 in a study in which alogliptin 12.5 or 25 mg was added to sulfonylurea monotherapy. 20 The mean change from baseline in HbA1c observed in the subgroup of patients on sulfonylurea and metformin in the present study was also numerically higher than the change from baseline in HbA1c at Week 24 observed when 5 mg saxagliptin was added to sulfonylurea and metformin treatment. 21 The change from baseline in HbA1c observed at Week 24 in the subgroup of patients on sulfonylurea and metformin was consistent with that observed in another global study in which sitagliptin was added for patients taking sulfonylurea and metformin.
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The results from the present study suggest that the glycemic efficacy of the addition of sitagliptin to patients taking sulfonylurea (with or without metformin) is consistent to that observed when sitagliptin was used as monotherapy (Chinese subgroup from a study conducted in Chinese, Korean, and Indian patients 12 ), or when added to metformin in Chinese patients with T2DM. 13 Furthermore, consistent with the mechanism of action of sitagliptin, the incidence of hypoglycemia observed in the present study when sitagliptin was added to sulfonylurea, an agent associated with hypoglycemia, was higher than when it was used in monotherapy, 12 or added to metformin, an agent not associated with hypoglycemia, in Chinese patients with T2DM. 13 Some limitations of the present study should be noted. The short duration of this trial precludes evaluation of long-term glycemic control and adverse events. In addition, the study was conducted only in Chinese patients living in China and the results may not be generalizable to other populations. However, the results are consistent with a similarly designed multinational study, 15 and with those of a similarly designed study conducted in other Asian populations, 13, 14 supporting the results of the present study. 
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